NCT02192502View on ClinicalTrials.gov

Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

149

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 29, 2020

Conditions

Postoperative Kidney Injury

Interventions

DRUG

human albumin 5%

DRUG

HES 130/0.4 (Voluven)

Trial Locations (1)

44195

Cleveland Clinic Foundation, Cleveland

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Fresenius Kabi

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT02192502 - Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients | Biotech Hunter | Biotech Hunter